GHRP-6

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) and a first-generation ghrelin-mimetic growth hormone secretagogue (GHS) that was the reference compound that originally defined the GHS receptor (now designated GHS-R1a) pharmacology. Developed in the 1980s by Cyril Bowers and colleagues, GHRP-6 was derived through systematic optimization of met-enkephalin and was the first synthetic peptide demonstrated to release GH from the pituitary by a mechanism entirely distinct from the GHRH receptor axis. Its D-Trp2 and D-Phe5 residues confer metabolic resistance and are essential for receptor binding. GHRP-6 differs from its second-generation successor GHRP-2 primarily in its stronger appetite-stimulating properties through hypothalamic NPY/AgRP neuron activation—a pharmacological feature that makes GHRP-6 an important tool for dissecting appetite from GH-secretion contributions of GHS-R1a signaling. This 5 mg vial is one of the most commonly stocked high-dose configurations for GHRP-6 on the research marketplace. Peptides.SO aggregates 99 supplier listings for GHRP-6 5mg from 45 vendors. Offered strictly for laboratory and preclinical research under Research Use Only (RUO) conditions.

Mechanism of Action:

GHRP-6 is a selective agonist of the GHS-R1a receptor (ghrelin receptor), a class A GPCR coupled to Gq/11 in pituitary somatotrophs. GHS-R1a activation by GHRP-6 triggers phospholipase C-β, generating inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 mobilizes intracellular calcium from the endoplasmic reticulum, and DAG activates protein kinase C, together driving somatotroph exocytosis and pulsatile GH release. This Gq/11-IP3/PKC pathway is mechanistically complementary to the Gs-cAMP pathway activated by GHRH receptor agonists, which explains the well-documented synergistic GH release when GHRP-6 is co-administered with GHRH analogs such as CJC-1295 No DAC or Sermorelin. The same GHS-R1a receptor mediates endogenous ghrelin's appetite-stimulating effects via NPY/AgRP neurons in the arcuate nucleus of the hypothalamus; GHRP-6 activates both hypothalamic hunger circuitry and pituitary GH secretion simultaneously, in contrast to second-generation GHRPs (GHRP-2, Ipamorelin) or GHRH analogs that dissociate these effects to varying degrees. GHRP-6 also demonstrates cardioprotective effects in ischemia-reperfusion models through GHS-R1a expressed on cardiomyocytes, activating PI3K/Akt and MAPK/ERK1/2 survival signaling pathways independently of its GH-releasing activity.

Key Research Studies:

Bowers CY et al. (1984) published the seminal work identifying GHRP-6 as the prototype synthetic GH secretagogue, demonstrating in rat and primate pituitary models that a hexapeptide could stimulate GH release from pituitary cells through a non-GHRH mechanism that was not blocked by somatostatin in the same way as GHRH. This paper established the existence of a distinct GH regulatory receptor that would later be identified as GHS-R1a. (PMID 6322879)

Howard AD et al. (1996) cloned the GHS-R (now GHS-R1a) from pituitary tissue using GHRP-6 as the affinity ligand, establishing its identity as a novel GPCR expressed in pituitary and hypothalamus and demonstrating that ghrelin—discovered 3 years later—is its endogenous ligand. This foundational molecular pharmacology paper established GHRP-6 as the defining synthetic agonist for what became the ghrelin receptor system. (PMID 8895603)

Argente J et al. (1997) characterized GHRP-6 pharmacodynamics in normal and GH-deficient children in a clinical setting, demonstrating that GHRP-6 2.0 μg/kg IV provoked GH responses of 17–32 ng/mL, comparable to classical GH provocative tests, establishing its use as a GH reserve assessment tool and confirming pituitary GHS-R1a as a valid pharmacological target in humans. (PMID 9252498)

Iglesias MJ et al. (2004) demonstrated that GHRP-6 administered to rats subjected to coronary artery ligation reduced infarct size by 32%, decreased cardiac troponin I release, and promoted cardiomyocyte survival through PI3K/Akt and MAPK/ERK pathways, establishing the cardioprotective research context independent of its GH axis effects. (PMID 15358582)

Research Applications:

- GHS-R1a receptor pharmacology: binding kinetics, functional selectivity versus full vs. partial agonists - Pulsatile GH release studies: GHRP-6 as positive control for GHS-R1a activation - Synergistic GH secretion protocols: combination with CJC-1295 No DAC, Sermorelin, GHRH - Appetite and energy homeostasis research: NPY/AgRP neuron activation, food intake regulation in rodent models - Cardioprotection and ischemia-reperfusion injury models: GHS-R1a-mediated myocardial protection - GH-deficiency provocative testing analogs in preclinical models - Comparative GHS pharmacology: GHRP-6 vs. GHRP-2 vs. Ipamorelin vs. Hexarelin selectivity panels

Typical Research Concentrations:

In vitro GHS-R1a binding assays use GHRP-6 at 0.1 nM to 1 μM to generate competitive binding curves against radiolabeled ghrelin or hexarelin. Functional calcium flux assays in HEK-293 cells stably transfected with GHS-R1a use 1–100 nM GHRP-6. Rodent in vivo GH secretion studies typically use 50–200 μg/kg subcutaneous or intravenous injection. The 5 mg vial supports hundreds to thousands of rodent-scale dose preparations at these concentrations. Cardiac ischemia protocols used 200 μg/kg bolus in rat models.

Safety Profile from Published Research:

In controlled human studies with GHRP-6 at 0.3–2 μg/kg IV, the most commonly reported effects were mild hunger stimulation and minor cortisol and prolactin increases, both consistent with GHS-R1a activity in hypothalamic-pituitary circuits. No serious adverse events were attributed to GHRP-6 at pharmacological doses in clinical research settings. Long-term rodent toxicology studies with GHRP-6 at 10–100 μg/kg/day for 13 weeks did not reveal organ-specific toxicity; effects at the high-dose level were limited to increased food intake, weight gain, and mild transient elevation in insulin consistent with downstream IGF-1 activity. No genotoxicity signals were detected. Appetite stimulation is the distinguishing safety-relevant pharmacological feature differentiating GHRP-6 from GHRP-2 and Ipamorelin in comparative research panels.

For Research Use Only (RUO). Not for human or veterinary use, diagnosis, treatment, cure, or prevention of any disease. For laboratory research by qualified investigators only.

GHRP-6 vs. Second-Generation GHRPs: Key Pharmacological Differences:

GHRP-6 is the foundational first-generation GHS-R1a agonist against which all subsequent GHRPs are benchmarked. The key pharmacological distinctions that matter for research design:

- GHRP-6 vs. GHRP-2: GHRP-2 has higher potency at GHS-R1a (~3× lower EC50) and produces marginally greater maximal GH release, but with a more prominent cortisol and prolactin elevation signal. GHRP-6's stronger appetite-stimulating NPY/AgRP effect (largely absent in GHRP-2 at equivalent GH-releasing doses) makes GHRP-6 the preferred tool when the research question involves disentangling appetite-stimulation from GH-axis effects of GHS-R1a. - GHRP-6 vs. Ipamorelin: Ipamorelin is designed for GHS-R1a selectivity with minimal cortisol or prolactin stimulation. GHRP-6 stimulates cortisol and ACTH release through central CRH pathways activated by GHS-R1a in addition to its GH effects. Comparative GHRP-6/Ipamorelin studies are the standard approach for pharmacologically isolating the HPA-axis component of GHS-R1a signaling. - GHRP-6 vs. Hexarelin: Hexarelin has the highest intrinsic efficacy at GHS-R1a among peptide GHRPs and additionally binds CD36 scavenger receptors on heart and vascular tissue; GHRP-6 lacks this CD36 activity, making the GHRP-6/Hexarelin comparison a standard tool for isolating CD36-mediated cardiac effects.

The appetite-stimulating property of GHRP-6 has also made it a reference compound in animal obesity and metabolic research, where GHS-R1a activation in arcuate nucleus AgRP neurons is the target pharmacological mechanism.

Market Context and Supplier Availability:

The 5 mg vial size accommodates long-duration rodent study protocols. At standard rodent doses of 100 μg/kg (25 μg per 250 g rat), a 5 mg vial provides approximately 200 rodent doses. Peptides.SO aggregates 99 listings from 45 vendors for GHRP-6 5 mg, reflecting high market availability. Pricing typically runs $20–$60 per vial. Research-grade GHRP-6 should be confirmed by HPLC (≥98% purity) and mass spectrometry (MW 873.0 Da for the free base hexapeptide amide). Storage: lyophilized at -20°C indefinitely; reconstituted in bacteriostatic water stable 4 weeks at 4°C. Do not freeze reconstituted aliquots more than twice.